Moneycontrol PRO
Open App
Live Now | Traders Conclave 2022 | India's Largest Retail Stock Investors & Traders Residential Conclave
you are here: HomeNewsTrendsHealth

Remdesivir to be used in patients with moderate to severe COVID-19: Health ministry

According to the clinical guidance issued by the Union health ministry for management of the infection in adult patients, Remdesivir has been asked to be used in patients with moderate to severe COVID-19 and those with no renal or hepatic dysfunction within 10 days of onset of any symptom.

December 24, 2021 / 09:18 PM IST
(Image: Reuters)

(Image: Reuters)

The Centre on Friday said Remdesivir drug should only be used in patients with moderate to severe’ COVID-19 and those with no renal or hepatic dysfunction within 10 days of the onset of any symptom.

It also warned against use of the drug in patients who are not on oxygen support or in home settings.

According to the clinical guidance issued by the Union health ministry for management of the infection in adult patients, Remdesivir has been asked to be used in patients with moderate to severe COVID-19 and those with no renal or hepatic dysfunction within 10 days of onset of any symptom.

The Tocilizumab drug may be considered for use in the presence of severe disease (preferably within 24 to 48 hours of onset of severe disease/ICU admission), according to the guidelines.

Tocilizumab can be used in case of significantly raised inflammatory markers (CRP &/or IL-6), condition not improving despite use of steroids and no active bacterial/fungal/tubercular infection.

Close

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

The ministry also said that those above 60 years of age, with cardiovascular disease, hypertension, diabetes and other immunocompromised states are at high risk for severe disease and mortality.

According to the guidelines, coronavirus patients have been classified into those affected by mild, moderate and severe disease.

For mild disease, home isolation and care is recommended, while admission in a ward is recommended for those battling moderate disease and ICU has been recommended for patients with severe COVID-19, they added.
PTI
first published: Dec 24, 2021 09:18 pm
Sections
ISO 27001 - BSI Assurance Mark